1. Home
  2. LCTX vs AMWL Comparison

LCTX vs AMWL Comparison

Compare LCTX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • AMWL
  • Stock Information
  • Founded
  • LCTX 1990
  • AMWL 2006
  • Country
  • LCTX United States
  • AMWL United States
  • Employees
  • LCTX N/A
  • AMWL N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMWL Retail: Computer Software & Peripheral Equipment
  • Sector
  • LCTX Health Care
  • AMWL Technology
  • Exchange
  • LCTX Nasdaq
  • AMWL Nasdaq
  • Market Cap
  • LCTX 165.6M
  • AMWL 165.7M
  • IPO Year
  • LCTX N/A
  • AMWL 2020
  • Fundamental
  • Price
  • LCTX $0.89
  • AMWL $8.91
  • Analyst Decision
  • LCTX Strong Buy
  • AMWL Hold
  • Analyst Count
  • LCTX 3
  • AMWL 4
  • Target Price
  • LCTX $5.67
  • AMWL $15.67
  • AVG Volume (30 Days)
  • LCTX 327.9K
  • AMWL 49.3K
  • Earning Date
  • LCTX 11-07-2024
  • AMWL 10-30-2024
  • Dividend Yield
  • LCTX N/A
  • AMWL N/A
  • EPS Growth
  • LCTX N/A
  • AMWL N/A
  • EPS
  • LCTX N/A
  • AMWL N/A
  • Revenue
  • LCTX $6,186,000.00
  • AMWL $254,911,000.00
  • Revenue This Year
  • LCTX N/A
  • AMWL $3.68
  • Revenue Next Year
  • LCTX $119.00
  • AMWL $24.78
  • P/E Ratio
  • LCTX N/A
  • AMWL N/A
  • Revenue Growth
  • LCTX N/A
  • AMWL N/A
  • 52 Week Low
  • LCTX $0.77
  • AMWL $5.00
  • 52 Week High
  • LCTX $1.61
  • AMWL $31.60
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 48.24
  • AMWL 53.36
  • Support Level
  • LCTX $0.83
  • AMWL $7.80
  • Resistance Level
  • LCTX $0.94
  • AMWL $8.62
  • Average True Range (ATR)
  • LCTX 0.05
  • AMWL 0.36
  • MACD
  • LCTX 0.00
  • AMWL 0.03
  • Stochastic Oscillator
  • LCTX 41.92
  • AMWL 60.77

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About AMWL American Well Corporation

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

Share on Social Networks: